JP7301220B2 - Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 - Google Patents
Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 Download PDFInfo
- Publication number
- JP7301220B2 JP7301220B2 JP2022513541A JP2022513541A JP7301220B2 JP 7301220 B2 JP7301220 B2 JP 7301220B2 JP 2022513541 A JP2022513541 A JP 2022513541A JP 2022513541 A JP2022513541 A JP 2022513541A JP 7301220 B2 JP7301220 B2 JP 7301220B2
- Authority
- JP
- Japan
- Prior art keywords
- pmas
- intestinal
- present application
- analysis
- chain fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
- G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00743—Type of operation; Specification of treatment sites
- A61B2017/00818—Treatment of the gastro-intestinal system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Endocrinology (AREA)
Description
実施例1.PMAS(Personalized Pharmaceutical Meta-Analysis Screening)技法を利用したパーソナライズ候補物質スクリーニングシステムの全般的な過程
本願は、個人の糞便などの試料を利用してパーソナライズプロバイオティクス、食品、健康機能性食品及び医薬品などを体外(in vitro)条件でスクリーニングするための組成物及び方法に関し、本願においては、上記スクリーニングシステムをPMAS(Personalized Pharmaceutical Meta-Analysis Screening)と称しながら説明する。
ヒト又は動物の糞便とPMAS培地とを1:12の割合で混合し、ストマッカー(stomacher)を利用して均質化した後、フィルタネットを利用して便の残余物は取り除く。プロバイオティクス、食品、健康機能性食品及び医薬品候補物質の処置に先立ち、便と培地が混ざった混合物を嫌気チャンバ内において4時間還元する。
嫌気チャンバ内において糞便と培地の均質化された混合物を96-ウェルプレートなどの培養プレートにそれぞれ同一量ずつ分注する。
処理するプロバイオティクス、食品、健康機能性食品及び医薬品候補物質は滅菌済みの1xPBSに懸濁させ、濃度と量を均一化して糞便-培地混合物が入っている培養プレートにそれぞれ分注する。
温度、湿度及びモーションを腸内環境と類似に形成したまま嫌気条件においてプレートを培養することで、各実験群を醗酵培養させる。
培養されたそれぞれの実験群を遠心分離することで上澄液と沈殿物(pallet)とを分離した後、上澄液から代謝体、短鎖脂肪酸、毒性物質などを分析し、沈殿物から腸内細菌叢の分析を行う。
上記実施例1のPMAS技法において、サンプル分析ステップの過程の一例示図を図2及び図3に示す。
上記実施例2のサンプル分析結果を基にパーソナライズプロバイオティクス、食品、健康機能性食品及び医薬品などをスクリーニングする過程の一例示図を図4に示す。
上記実施例1のPMAS技法で使用するためのPMAS培地の最適の組成を確認するために、下記のような実験を行った。
上記実施例1のPMAS技法において、嫌気培養ステップにおける最適の培養時間を確認するために、下記のような実験を行った。
本願のPMAS技法を利用し、個々人の腸内環境を体外(in vitro)条件で形成してパーソナライズ候補物質を正確にスクリーニングできるか否かの有効性を確認するために、下記の実験を行うことで確認した。
本願のPMAS技法を利用した分析結果が同一個体で繰り返して再現されるか否かを確認するために、下記のような実験を行った。
本願のPMAS技法を利用した分析結果が実際の臨床結果と同一性を示しているか否かを確認するために、下記のような実験を行った。
上記実施例1乃至実施例3及び実験例1乃至3で説明したPMAS技法を利用すれば、下記のように個々人の腸内環境を体外条件で迅速で且つ正確に分析し、それを基に腸内環境を改善できる候補物質をスクリーニングすることができる。下記の説明は、PMAS技法を利用したスクリーニングシステムの一例示であり、当該技術分野において通常の知識を有する者であれば、上記記載から様々な修正及び変形が可能である。例えば、説明された技術が説明された方法とは異なる順番で行われるか、及び/又は説明されたシステム、構造、装置、過程などの構成要素が説明された方法とは異なる形態で結合又は組み合わせられるか、他の構成要素又は均等物によって対置あるいは置換されても適切な結果が達成されることができる。
96-ウェルプレートに8つの互いに異なるヒトの糞便サンプルをそれぞれPMAS培地と混合及び均質化して同一量ずつ分配し(横軸)、上記糞便サンプルが分注された96-ウェルプレートに縦に互いに異なる候補物質を処理した(図9)。
上記(1)と同じ方法で100名の互いに異なる成人の糞便サンプルを利用してPMAS検査を行い、それによる酪酸量の変化を分析して、それを図10に示した。
上記(1)と同じ方法で100名の互いに異なる成人の糞便サンプルを利用してPMAS検査を行い、このうち一部のサンプルに対する腸内微生物多様性の変化を分析して、それを図11に示した。
上記(1)と同じ方法で100名の互いに異なる成人の糞便サンプルを利用してPMAS検査を行い、それによる初期糞便サンプルの微生物構成とPMAS検査後の酪酸量変化の相関関係を分析して、それを図12に示した。
Claims (3)
- 腸内環境改善物質をスクリーニングするための培地であって、
L-システイン(L-cystein)を含み、
前記L-システイン(L-cystein)とムチン(Mucin)以外の炭素源及び窒素源を含まない、培地。 - 前記培地は、ムチン(Mucin)をさらに含む、請求項1に記載の培地。
- 前記腸内環境改善物質は、プロバイオティクス、プレバイオティクス、食品、健康機能性食品及び医薬品からなる群より選択される1つ以上である、請求項1に記載の培地。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023071270A JP2023093682A (ja) | 2019-08-30 | 2023-04-25 | Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0107146 | 2019-08-30 | ||
KR1020190107146A KR102124474B1 (ko) | 2019-08-30 | 2019-08-30 | Pmas방법을 이용한 개인 맞춤형 장내 환경 개선 물질 스크리닝 방법 |
PCT/KR2020/001485 WO2021040159A1 (ko) | 2019-08-30 | 2020-01-31 | Pmas 방법을 이용한 개인 맞춤형 장내 환경 개선 물질 스크리닝 방법 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023071270A Division JP2023093682A (ja) | 2019-08-30 | 2023-04-25 | Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022547435A JP2022547435A (ja) | 2022-11-14 |
JP7301220B2 true JP7301220B2 (ja) | 2023-06-30 |
Family
ID=74681728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022513541A Active JP7301220B2 (ja) | 2019-08-30 | 2020-01-31 | Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11237172B2 (ja) |
EP (1) | EP3988664A4 (ja) |
JP (1) | JP7301220B2 (ja) |
CN (1) | CN114341363A (ja) |
AU (1) | AU2020337596A1 (ja) |
CA (1) | CA3148749A1 (ja) |
MY (1) | MY197412A (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006288272A (ja) | 2005-04-11 | 2006-10-26 | Ajinomoto Co Inc | システイン含有培地を用いる微生物の取得方法 |
JP2009542245A (ja) | 2006-07-13 | 2009-12-03 | コンパニー・ゲルベ・ダノン | システイン顆粒およびビフィドバクテリウムアニマリスラクティスの成長刺激剤としてのその使用 |
JP2015520176A (ja) | 2012-06-06 | 2015-07-16 | シャンハイ ジャオ トン ユニバーシティ | 腸内細菌叢集団を改善する方法および組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6006117B2 (ja) * | 2009-11-12 | 2016-10-12 | ネステク ソシエテ アノニム | 腸内微生物叢バランス及び健康を促進するための栄養組成物 |
EP2700715B1 (de) | 2012-08-20 | 2018-07-25 | Evonik Degussa GmbH | Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
CN105796541A (zh) * | 2015-12-16 | 2016-07-27 | 何松庆 | 一种治疗炎症性肠病的组方 |
BR112018074355A2 (pt) * | 2016-05-24 | 2019-03-06 | Shafer Kim | composição de probióticos e enzimas digestivas e método de preparação e uso do mesmo |
KR101909083B1 (ko) * | 2016-08-02 | 2018-10-17 | 한국과학기술연구원 | 실리마린을 포함하는 장 건강 개선용 조성물 |
-
2020
- 2020-01-31 EP EP20856035.9A patent/EP3988664A4/en active Pending
- 2020-01-31 MY MYPI2022000433A patent/MY197412A/en unknown
- 2020-01-31 AU AU2020337596A patent/AU2020337596A1/en active Pending
- 2020-01-31 CN CN202080060535.1A patent/CN114341363A/zh active Pending
- 2020-01-31 CA CA3148749A patent/CA3148749A1/en active Pending
- 2020-01-31 JP JP2022513541A patent/JP7301220B2/ja active Active
- 2020-07-17 US US16/932,626 patent/US11237172B2/en active Active
-
2021
- 2021-12-21 US US17/645,451 patent/US20230213526A9/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006288272A (ja) | 2005-04-11 | 2006-10-26 | Ajinomoto Co Inc | システイン含有培地を用いる微生物の取得方法 |
JP2009542245A (ja) | 2006-07-13 | 2009-12-03 | コンパニー・ゲルベ・ダノン | システイン顆粒およびビフィドバクテリウムアニマリスラクティスの成長刺激剤としてのその使用 |
JP2015520176A (ja) | 2012-06-06 | 2015-07-16 | シャンハイ ジャオ トン ユニバーシティ | 腸内細菌叢集団を改善する方法および組成物 |
Non-Patent Citations (2)
Title |
---|
Utilization of amino acids and peptides by Fusobacterium nucleatum,Scand J Dent Res.,Vol. 97,1989年,p.43- 53 |
便秘診療の最前線,日本消化器病学会雑誌,2018年,Vol. 115, No. 11,p. 940-949 |
Also Published As
Publication number | Publication date |
---|---|
US11237172B2 (en) | 2022-02-01 |
MY197412A (en) | 2023-06-16 |
JP2022547435A (ja) | 2022-11-14 |
EP3988664A4 (en) | 2023-06-21 |
AU2020337596A1 (en) | 2022-02-10 |
US20210063407A1 (en) | 2021-03-04 |
CA3148749A1 (en) | 2021-03-04 |
US20230213526A9 (en) | 2023-07-06 |
US20220187305A1 (en) | 2022-06-16 |
CN114341363A (zh) | 2022-04-12 |
EP3988664A1 (en) | 2022-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023093682A (ja) | Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 | |
Stanley et al. | Bacteria within the gastrointestinal tract microbiota correlated with improved growth and feed conversion: challenges presented for the identification of performance enhancing probiotic bacteria | |
Prakash et al. | Gut microbiota: next frontier in understanding human health and development of biotherapeutics | |
Kang et al. | Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone | |
West et al. | Probiotics during weaning reduce the incidence of eczema | |
Wang et al. | A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of the gut microbiota and relief from chronic constipation | |
Mohr et al. | Probiotic supplementation has a limited effect on circulating immune and inflammatory markers in healthy adults: A systematic review of randomized controlled trials | |
Hollister et al. | Characterization of the stool microbiome in hispanic preschool children by weight status and time | |
Swann et al. | Considerations for the design and conduct of human gut microbiota intervention studies relating to foods | |
CN110176305A (zh) | 一种利用高通量基因测序评估肠道菌群健康的方法 | |
Lenhart et al. | Effect of exclusion diets on symptom severity and the gut microbiota in patients with irritable bowel syndrome | |
JP2022512681A (ja) | Car t細胞療法応答不良のリスクがある対象を識別および処置するための方法および組成物 | |
Chenhuichen et al. | Impact of probiotics and prebiotics in the modulation of the major events of the aging process: A systematic review of randomized controlled trials | |
Asuncion et al. | The effects of fresh mango consumption on gut health and microbiome–Randomized controlled trial | |
CN107208037A (zh) | 拟杆菌属在预防和治疗冠状动脉疾病中的用途 | |
Oda et al. | Improvement in human immune function with changes in intestinal microbiota by Salacia reticulata extract ingestion: a randomized placebo-controlled trial | |
Li et al. | Consistent alterations of human fecal microbes after transplantation into germ-free mice | |
KR102227382B1 (ko) | Pmas방법을 이용한 개인 맞춤형 장내 환경 개선 물질 스크리닝 방법 | |
JP7301220B2 (ja) | Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 | |
EP4368730A2 (en) | Microbiome interventions | |
Li et al. | Multi-omics analyses reveal relationships among polyphenol-rich oolong tea consumption, gut microbiota, and metabolic profile: a pilot study | |
Jin et al. | Analysis of the human intestinal microbiota from 92 volunteers after ingestion of identical meals | |
Kleniewska et al. | Assessment of human 4-hydroxynonenal, 8-isoprostane concentrations and glutathione reductase activity after synbiotics administration | |
CN113631724A (zh) | 用于确定犬科动物的微生物组的年龄状态的监测工具和诊断方法 | |
Baenas et al. | Probiotic and prebiotic interventions in eating disorders: A narrative review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230425 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230620 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7301220 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |